Fig. 3
From: Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy
A Western blot analysis of the expression levels of oxidative phosphorylation system complexes in untreated (control, DMSO) and treated JJN3 cells exposed to urolithin A (UroA) for 48 h. The complexes studied were as follows: NADH dehydrogenase beta subcomplex subunit 8 of complex I (NDUFB8), succinate dehydrogenase subunit B of complex II (SDHB), cytochrome c oxidase complex subunit 1 of complex IV (MTCO1), cytochrome b-c1 complex subunit 2 of complex III (UQCRC2), and ATP synthase subunit alpha of complex V (ATP5A). Bar graphs represent the mean ± SEM of the expression of the complexes normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. B Immunocytochemistry analysis of HNE adduction in JJN3 cells after exposure to DMSO or UroA at different concentrations for 48 h. Bar chart shows the percentage of stained (+ or + + levels of intensity) or non-stained ( −) cells. C Western blot analysis of the expression levels of NRF2 in untreated (control, DMSO) and treated JJN3 cells exposed to urolithin A (UroA) for 48 h. Bar graphs represent the mean ± SEM of the expression of the complexes normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. *P ≤ 0.05; **P ≤ 0.01